Lipid Metabolism and Cardiometabolic Disease

Update item information
Identifier lipid_metabolism_and_cardiometabolic_disease
Title Lipid Metabolism and Cardiometabolic Disease
Creator Summers, S.A.; Nutrition & Integrative Physiology; College of Health; University of Utah Health
Subject Diffusion of Innovation; Lipid Metabolism; Metabolic Syndrome; Ceramides; Adipose Tissue; Fatty Liver; Non-alcoholic Fatty Liver Disease; Diabetes Mellitus; Glucose; Coronary Artery Disease; Biomarkers; Apoptosis; Homeostasis; Drug Discovery; Knowledge Discovery
Keyword Diabetes and Metabolism
Image Caption Ceramides are signals of lipid excess that inhibit glucose utilization and induce lipid accumulation and hepatocyte apoptosis - all key features of the Metabolic Syndrome.
Description Metabolic diseases such as diabetes, steatohepatitis, and coronary artery disease result from the delivery of nutrients that exceed a tissue's energetic needs or storage capacity. The excess nutrients give rise to deleterious lipid species that impair cellular function. Summers and colleagues found that ceramides, a class of sphingolipids, alter metabolism of liver and adipose tissue in a way that gives rise to cardiometabolic disease. They also discovered that removing a single double-bond from ceramides is sufficient to restore metabolic homeostasis in diseased rodents. Lastly, they discovered that circulating ceramides were potent biomarkers of coronary artery disease. These data have inspired drug discovery efforts to lower ceramides and improve cardiometabolic health.
Relation is Part of 2019
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Date Digital 2020
Date 2019
Type Image
Format image/jpeg
Rights Management Copyright © 2021, University of Utah, All Rights Reserved
Language eng
ARK ark:/87278/s66f1h47
References 1.) Targeting a ceramide double bond improves insulin resistance and hepatic steatosis. Chaurasia B, Tippetts TS, Mayoral Monibas R, Liu J, Li Y, Wang L, Wilkerson JL, Sweeney CR, Pereira RF, Sumida DH, Maschek JA, Cox JE, Kaddai V, Lancaster GI, Siddique MM, Poss A, Pearson M, Satapati S, Zhou H, McLaren DG, Previs SF, Chen Y, Qian Y, Petrov A, Wu M, Shen X, Yao J, Nunes CN, Howard AD, Wang L, Erion MD, Rutter J, Holland WL, Kelley DE, Summers SA. Science. 2019 Jul;365(6451):386. 2.) Metabolic messengers: Ceramides. Summers SA, Chaurasia B, Holland WL Nature Metabolism. 2019 Oct:1051. 3.) Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease. Poss AM, Maschek JA, Cox JE, Hauner BJ, Hopkins PN, Hunt SC, Holland WL, Summers SA, Playdon MC. J Clin Invest. 2019 Nov. pii: 131838. See also: Tiny Change Has Big Effects, Reverses Prediabetes in Mice (; People with High Ceramide Levels Up to Four Times More Likely to Have Heart Attacks, Stroke (
Press Releases and Media Science Daily; Fierce Biotech; Nutrition Insight; KSL; Genetic Engineering and Biotechnology News; Science Codex; Science Blog; Health Medicine Network; Science Daily; MyHealthyClick.
Setname ehsl_50disc
Date Created 2020-08-13
Date Modified 2021-05-06
ID 1589392
Reference URL
Back to Search Results